Indian M&A deals top $1.5B in 2015 led by overseas acquisitions

Overseas acquisitions by Indian drugmakers were at a 5-year high this year and topped $1.5 billion compared to just $251 million in 2014, according to a report by Livemint. Using data from VCCEdge, the report said the "sharp increase" in M&A deals was the result of consolidation in the U.S. generics market and a high-risk "appetite" by Indian companies.

The deals were highlighted by the July acquisition of U.S.-based Gavis Pharmaceuticals by India's Lupin for $880 million and also by the September acquisition of InvaGen Pharmaceuticals and Exelan Pharmaceuticals by Cipla for $550 million, according to the report. Another deal of note was the May acquisition of Aspen Pharmacare's Australia business by Strides Arcolab for $287 million.

The report also said inbound deals into India doubled to $999 million compared to $430 million in 2014. Deals of note here included the February acquisition of India's Famy Care by Mylan ($MYL) for about $800 million and in October Recipharm said it would buy a majority stake in injectable contract manufacturer Nitin Lifesciences for $100 million.

The report also highlighted several hospital deals that included a $200 million majority stake sale in Hyderabad-based Ravindranath GE Medical Associates by Malaysia's IHH Healthcare in August and the March acquisition by IHH Healthcare which bought a majority stake in India's Continental Hospitals for $45.4 million.

Most recently, New Jersey-based startup Bionpharma said it has acquired about 25 products from India's Banner Life Sciences that generate about $70 million in annual revenues, according to a report in the Economic Times.

- here's the report by Livemint
- and one from the Economic Times

Suggested Articles

The Shire bid Takeda’s been discussing is getting real. The Japanese drugmakers is gauging lender interest in financing the buy.

After initial doubts, some analysts now like Takeda's chances of pulling off a deal for embattled Shire.

Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.